Sponsors (2)
The bill directs substantial, multi‑year funding and infrastructure support toward high‑risk biomedical research and increases transparency, at the cost of concentrating awards, restricting recipients from other federal grants, adding administrative burdens, and increasing federal spending commitments.
Scientists and research institutions receive stable, multi‑year funding ($5M–$50M/year for 7 years) that enables high‑risk, high‑reward biomedical research projects.
Nonprofit funders can regrant program funds to early‑stage teams and projects that are unlikely to win traditional NIH grants, increasing support for unconventional or breakthrough ideas.
Creates an explicit funding category for research capacity (R&D plant and large equipment), enabling modernization and expansion of lab infrastructure at universities and research centers.
All taxpayers and other NIH programs face larger multi‑year federal spending obligations that could reduce funding available for existing NIH priorities and initiatives.
Award recipients must forgo other federal research grants (except training awards) during the award period, reducing diversified funding streams and potential collaboration opportunities for institutions and investigators.
Concentrating large, multi‑year awards in select institutions risks crowding out smaller investigators and existing grant mechanisms, disadvantaging small labs, early career researchers, and small businesses.
Based on analysis of 2 sections of legislative text.
Creates a new NIH X‑Labs program to award competitive, long‑term institutional grants (typically $5M–$50M/year for seven years, renewable once) for breakthrough biomedical research and R&D infrastructure.
Introduced December 10, 2025 by Josh Harder · Last progress December 10, 2025
Creates a new NIH "X‑Labs" initiative that awards large, long‑term competitive institutional grants to support breakthrough biomedical research and purchase of R&D plant. Awards are organized into four XL categories with set award sizes and durations, special regranting rules for nonprofit awardees, and limited renewal authority subject to competitive review and available appropriations.